

April 21, 2026

Chairman Tom Cole
2207 Rayburn House Office Building
Washington, DC 20515

Senator Susan Collins
413 Dirksen Senate Office Building
Washington, DC 20510

Ranking Member Rosa DeLauro
2413 Rayburn House Office Building
Washington, DC 20515

Senator Patty Murray
154 Russell Senate Office Building
Washington, DC 20510

Chairman Mario Diaz-Balart
374 Cannon House Office Building
Washington, DC 20515

Senator Lindsey Graham
211 Russell Senate Office Building
Washington, DC 20510

Ranking Member Lois Frankel
2305 Rayburn House Office Building
Washington, DC 20515

Senator Brian Schatz
722 Hart Senate Office Building
Washington, DC 20510

Dear Chairman Cole, Ranking Member DeLauro, Chairman Diaz-Balart, Ranking Member Frankel, Senator Collins, Senator Murray, Senator Graham and Senator Schatz,

As representatives of leading American and global companies, we commend your continued bipartisan leadership on global health programs that save lives and advance American economic interests. Strategic health investments abroad keep workers and consumers safe, improve business operating environments and expand markets for American innovation. Among the most effective of these investments is the Global Fund to Fight AIDS, Tuberculosis and Malaria. We write about fiscal year 2027 funding, and release of all previous appropriations to the Global Fund. Since 2002, the Global Fund partnership has saved 70 million lives and reduced the combined death rate from AIDS, tuberculosis and malaria by 63 percent. In 2024 alone, Global Fund–supported programs placed 25.6 million people on life-saving antiretroviral therapy for HIV, treated 7.4 million people for TB, including 120,000 with drug-resistant TB, and distributed 162 million insecticide-treated mosquito nets to protect families from malaria.

These results are possible because of the Global Fund’s unique public-private partnership model, which harnesses the power of the market and the best practices of private businesses to deliver lifesaving results.

- **Private sector partnership:** The Global Fund works closely with the private sector, with private businesses and philanthropies participating in the governance of the Global Fund, with dedicated seats on its board. The private sector has invested more than \$5.3 billion in the Global Fund over the last twenty years and last year pledged more funding than ever before.
- **Shaping markets:** By crowding in funding from dozens of public and private donors, the Global Fund’s financing has a scale and reliability that allows it to invest in the full value chain for lifesaving health products, from development to delivery. It can place advance market commitments for products in development, which reduces the risk and cost of R&D.

It brings new products to market faster, with high quality standards and lower manufacturing costs. These investments mean the Global Fund can procure and deliver products like HIV therapies, TB tests and insecticide-treated bed nets at better prices and bigger scales. For example, the cost of first-line HIV treatments now cost as little as \$35 per patient per year—down from \$10,000 per year when the Global Fund began its work.

- **Efficiency and accountability:** The Global Fund is one of the most efficient international organizations, with low operating expenses that ensure 93.8% of funding goes to lifesaving programs. Its financing model is performance-based and supported by rigorous oversight, including a technical review panel that evaluates funding proposals, independent auditors that monitor programs in all countries and an independent Office of Inspector General.
- **Investing in America:** Since 2010, the Global Fund has procured more than \$3.5 billion in goods and services from American companies, creating jobs and increasing access to emerging and frontier markets for American investors.
- **Leveraging others' resources:** U.S. pledges and commensurate appropriations to the Global Fund have driven marked burden-sharing by other donors since 2004.

Recognizing the Global Fund's efficiency and effectiveness (and its benefits to America's own prosperity, competitiveness and security), the Trump administration pledged \$4.6 billion for the partnership's latest three-year funding cycle in November 2025. We applaud this commitment and urge Congress to fulfill one-third of the pledge by appropriating **\$1.533 billion in fiscal year 2027**. That investment would save an estimated 1.9 million lives and prevent 34 million new infections from HIV, TB and malaria. **We also ask that you continue to require that all funds previously appropriated for the Global Fund be delivered as quickly as possible.** Thank you for urging the executive branch to do so in the orderly execution of enacted funding. As the Global Fund has proven for more than two decades, it's a smart investment with lifesaving dividends.

Sincerely,

Atlas AI	Merck	SC Johnson
BASF Corporation	MinXray	Thermo Fisher Scientific
Danaher	Nexleaf Analytics	Vestergaard
Dimagi	Qure.ai	ViiV Healthcare
Gilead Sciences	(RED)	Zenysis
IQVIA	Roche Diagnostics	